论文部分内容阅读
目的分析多索茶碱与布地奈德联合治疗急性发作的支气管哮喘效果。方法选取支气管哮喘急性发作患者134例,随机分为两组,各67例。对照组给予布地奈德吸入,2吸(200μg)/次,2次/d;在此基础上,观察组给予多索茶碱片口服,200μg(1片)/次,2次/d。观察比较两组治疗前后FEV1、FVC、FEV1/FVC及IL-23、总有效率及不良反应发生情况。结果观察组总有效率为94.0%,显著高于对照组的82.1%(P<0.05),而口干、恶心、呕吐、面红等总发生率为10.4%,与对照组的7.5%比较,差异无统计学意义。治疗前两组FEV1/FVC等指标及血清IL-23水平比较,差异无统计学意义;治疗后两组均显著改善,且观察组改善幅度较大,组间比较差异有统计学意义(P<0.05)。结论对于支气管哮喘急性发作患者,多索茶碱与布地奈德联合有着显著效果,且口干、恶心、呕吐、面红等发生率增加不明显,值得推广。
Objective To analyze the efficacy of doxofylline and budesonide in the treatment of acute bronchial asthma. Methods A total of 134 acute exacerbation cases of bronchial asthma were selected and divided into two groups at random, 67 cases each. The control group was given budesonide inhalation, 2 inhalation (200μg) / times, 2 times / d; on this basis, the observation group was given doxofylline tablets orally, 200μg (1 tablet) / times, 2 times / d. The total effective rate and adverse reactions of FEV1, FVC, FEV1 / FVC and IL-23 before and after treatment in both groups were observed and compared. Results The total effective rate in the observation group was 94.0%, significantly higher than that in the control group (82.1%) (P <0.05), while the total incidence of dry mouth, nausea, vomiting and redness was 10.4% The difference was not statistically significant. Before treatment, FEV1 / FVC and other indicators of serum levels of IL-23 and no significant difference; after treatment, both groups were significantly improved, and the observation group improved marginally, the difference between the two groups was statistically significant (P < 0.05). Conclusions For patients with acute exacerbation of bronchial asthma, the combination of doxofylline and budesonide has a significant effect, and the incidence of dry mouth, nausea, vomiting, redness is not obvious, which is worth promoting.